Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis IV: Nursing Management

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Divergence From Temperate Models: Pollution Dominance and Stochastic Assembly in a Continental Freshwater System Under Compressed Modernity.

Global change biology·2026

Same author

Artificial recombinant high-density protein nanocarriers for precision drug delivery.

Chemical science·2026

Same author

High-accuracy camera calibration for underwater binocular laser scanner via virtual-imaging.

Optics express·2026

Same author

Boosting immunogenic tumour cell death via nanotherapeutic targeting of the Stanniocalcin 1 phagocytosis checkpoint for enhanced cancer immunotherapy.

Nature communications·2026

Same author

Novel insight of dynamic characteristics of typical terrestrial plant litter as potential organic source to waterbodies.

Environmental research·2025

Same author

Biomimetic liposomes in drug delivery: from design mechanisms to applications.

Chemical Society reviews·2025

Search research articles

Related Experiment Video

Updated: Sep 1, 2025

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Surface-modified nanotherapeutics targeting atherosclerosis.

Wenpan Li¹, Karina Marie Gonzalez¹, Jinha Chung¹

¹Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, Arizona, 85721, USA. lu6@pharmacy.arizona.edu.

Biomaterials Science

|August 18, 2022

Summary

Nanoparticle delivery systems offer advanced atherosclerosis treatment by targeting diseased tissues, minimizing side effects. This review explores ligand-modified nanoparticles for improved atherosclerosis therapy and future nanotherapeutic strategies.

More Related Videos

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Related Experiment Videos

Last Updated: Sep 1, 2025

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Area of Science:

Biomedical Engineering
Nanomedicine
Cardiovascular Research

Background:

Atherosclerosis is a chronic, metabolic disease posing significant health risks.
Current diagnostic and therapeutic methods for atherosclerosis have limitations.
Nanotechnology presents novel avenues for atherosclerosis treatment.

Purpose of the Study:

To review research on ligand-modified nanoparticles for atherosclerosis targeting.
To discuss design strategies and limitations of current nanocarriers.
To outline future directions for nanotherapeutics in atherosclerosis.

Main Methods:

Literature review of nanotechnology applications in atherosclerosis.
Analysis of ligand-modified nanoparticle systems for targeted delivery.
Evaluation of current challenges and future prospects in nanomedicine for atherosclerosis.

Main Results:

Surface-modified nanoparticles show potential for targeted atherosclerosis therapy.
Ligand modification enhances binding to overexpressed receptors on atherosclerotic tissues.
Targeted delivery can improve therapeutic efficacy and reduce off-target effects.

Conclusions:

Ligand-modified nanoparticles represent a promising strategy for atherosclerosis treatment.
Further research is needed to overcome current vector design limitations.
This review provides insights for developing next-generation atherosclerosis nanotherapeutics.